This dataset contains de-identified routinely collected eye examination results for over 3000 individuals seeking eye care from the Australian College of Optometry. This data was collected from 1st January to 31st December 2018.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 12 elements for all COVID-19 cases shared with CDC and includes demographics, any exposure history, disease severity indicators and outcomes, presence of any underlying medical conditions and risk behaviors, and no geographic data.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

The following apply to all three datasets:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data cells are suppressed to protect individual privacy.
• The datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensures that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

The deidentified data in the “COVID-19 Case Surveillance Public Use Data” include demographic characteristics, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and presence of any underlying medical conditions and risk behaviors. All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 Case Reports

COVID-19 case reports have been routinely submitted using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for laboratory-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.
• Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question “Was the individual hospitalized?” where the possible answer choices include “Yes,” “No,” or “Unknown,” the blank value is recoded to Missing because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race and ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<5) records and indirect identifiers (e.g., date of first positive specimen). Suppression includes rare combinations of demographic characteristics (sex, age group, race/ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

For questions, please contact Ask SRRG (eocevent394@cdc.gov).

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These

The National Center for Advancing Translational Sciences (NCATS) has systematically compiled clinical, laboratory and diagnostic data from electronic health records to support COVID-19 research efforts via the National COVID Cohort Collaborative (N3C) Data Enclave. As of August 2, 2022, the repository contains information from over 15 million patients (including 5.8 million COVID-19 positive patients) across the United States.

The N3C Data Enclave is organized into 3 levels of data with varying access restrictions:

• Synthetic dataset: Contains no protected health information (PHI). This is a statistically-comparable artificial dataset derived from the original dataset.
  • Can be requested by: Researchers from US-based or foreign institutions, and citizen scientists
• De-identified dataset: Contains no PHI. This dataset consists of real patient data with shifted dates of service and truncated ZIP codes of patients residing in areas with populations above 20,000.
  • Can be requested by: Researchers from US-based or foreign institutions
• Limited Data Set (LDS): Contains 2 PHI elements (dates of service and patient ZIP code). This dataset consists of real patient data.
  • Can be requested by: Researchers from US-based institutions only

The NIHR is one of the main funders of public health research in the UK. Public health research falls within the remit of a range of NIHR Research Programmes, NIHR Centres of Excellence and Facilities, plus the NIHR Academy. NIHR awards from all NIHR Research Programmes and the NIHR Academy that were funded between January 2006 and the present extraction date are eligible for inclusion in this dataset. An agreed inclusion/exclusion criteria is used to categorise awards as public health awards (see below). Following inclusion in the dataset, public health awards are second level coded to one of the four Public Health Outcomes Framework domains. These domains are: (1) wider determinants (2) health improvement (3) health protection (4) healthcare and premature mortality.More information on the Public Health Outcomes Framework domains can be found here.This dataset is updated quarterly to include new NIHR awards categorised as public health awards. Please note that for those Public Health Research Programme projects showing an Award Budget of £0.00, the project is undertaken by an on-call team for example, PHIRST, Public Health Review Team, or Knowledge Mobilisation Team, as part of an ongoing programme of work.Inclusion criteriaThe NIHR Public Health Overview project team worked with colleagues across NIHR public health research to define the inclusion criteria for NIHR public health research awards. NIHR awards are categorised as public health awards if they are determined to be ‘investigations of interventions in, or studies of, populations that are anticipated to have an effect on health or on health inequity at a population level.’ This definition of public health is intentionally broad to capture the wide range of NIHR public health awards across prevention, health improvement, health protection, and healthcare services (both within and outside of NHS settings). This dataset does not reflect the NIHR’s total investment in public health research. The intention is to showcase a subset of the wider NIHR public health portfolio. This dataset includes NIHR awards categorised as public health awards from NIHR Research Programmes and the NIHR Academy. This dataset does not currently include public health awards or projects funded by any of the three NIHR Research Schools or any of the NIHR Centres of Excellence and Facilities. Therefore, awards from the NIHR Schools for Public Health, Primary Care and Social Care, NIHR Public Health Policy Research Unit and the NIHR Health Protection Research Units do not feature in this curated portfolio.DisclaimersUsers of this dataset should acknowledge the broad definition of public health that has been used to develop the inclusion criteria for this dataset. This caveat applies to all data within the dataset irrespective of the funding NIHR Research Programme or NIHR Academy award.Please note that this dataset is currently subject to a limited data quality review. We are working to improve our data collection methodologies. Please also note that some awards may also appear in other NIHR curated datasets. Further informationFurther information on the individual awards shown in the dataset can be found on the NIHR’s Funding & Awards website here. Further information on individual NIHR Research Programme’s decision making processes for funding health and social care research can be found here.Further information on NIHR’s investment in public health research can be found as follows: NIHR School for Public Health here. NIHR Public Health Policy Research Unit here. NIHR Health Protection Research Units here. NIHR Public Health Research Programme Health Determinants Research Collaborations (HDRC) here. NIHR Public Health Research Programme Public Health Intervention Responsive Studies Teams (PHIRST) here.

The PATH Study was launched in 2011 to inform the Food and Drug Administration's regulatory activities under the Family Smoking Prevention and Tobacco Control Act (TCA). The PATH Study is a collaboration between the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), and the Center for Tobacco Products (CTP), Food and Drug Administration (FDA). The study sampled over 150,000 mailing addresses across the United States to create a national sample of people who use or do not use tobacco. 45,971 adults and youth constitute the first (baseline) wave, Wave 1, of data collected by this longitudinal cohort study. These 45,971 adults and youth along with 7,207 "shadow youth" (youth ages 9 to 11 sampled at Wave 1) make up the 53,178 participants that constitute the Wave 1 Cohort. Respondents are asked to complete an interview at each follow-up wave. Youth who turn 18 by the current wave of data collection are considered "aged-up adults" and are invited to complete the Adult Interview. Additionally, "shadow youth" are considered "aged-up youth" upon turning 12 years old, when they are asked to complete an interview after parental consent. At Wave 4, a probability sample of 14,098 adults, youth, and shadow youth ages 10 to 11 was selected from the civilian, noninstitutionalized population (CNP) at the time of Wave 4. This sample was recruited from residential addresses not selected for Wave 1 in the same sampled Primary Sampling Unit (PSU)s and segments using similar within-household sampling procedures. This "replenishment sample" was combined for estimation and analysis purposes with Wave 4 adult and youth respondents from the Wave 1 Cohort who were in the CNP at the time of Wave 4. This combined set of Wave 4 participants, 52,731 participants in total, forms the Wave 4 Cohort. At Wave 7, a probability sample of 14,863 adults, youth, and shadow youth ages 9 to 11 was selected from the CNP at the time of Wave 7. This sample was recruited from residential addresses not selected for Wave 1 or Wave 4 in the same sampled PSUs and segments using similar within-household sampling procedures. This "second replenishment sample" was combined for estimation and analysis purposes with the Wave 7 adult and youth respondents from the Wave 4 Cohorts who were at least age 15 and in the CNP at the time of Wave 7. This combined set of Wave 7 participants, 46,169 participants in total, forms the Wave 7 Cohort. Please refer to the Restricted-Use Files User Guide that provides further details about children designated as "shadow youth" and the formation of the Wave 1, Wave 4, and Wave 7 Cohorts. Dataset 0002 (DS0002) contains the data from the State Design Data. This file contains 7 variables and 82,139 cases. The state identifier in the State Design file reflects the participant's state of residence at the time of selection and recruitment for the PATH Study. Dataset 1011 (DS1011) contains the data from the Wave 1 Adult Questionnaire. This data file contains 2,021 variables and 32,320 cases. Each of the cases represents a single, completed interview. Dataset 1012 (DS1012) contains the data from the Wave 1 Youth and Parent Questionnaire. This file contains 1,431 variables and 13,651 cases. Dataset 1411 (DS1411) contains the Wave 1 State Identifier data for Adults and has 5 variables and 32,320 cases. Dataset 1412 (DS1412) contains the Wave 1 State Identifier data for Youth (and Parents) and has 5 variables and 13,651 cases. The same 5 variables are in each State Identifier dataset, including PERSONID for linking the State Identifier to the questionnaire and biomarker data and 3 variables designating the state (state Federal Information Processing System (FIPS), state abbreviation, and full name of the state). The State Identifier values in these datasets represent participants' state of residence at the time of Wave 1, which is also their state of residence at the time of recruitment. Dataset 1611 (DS1611) contains the Tobacco Universal Product Code (UPC) data from Wave 1. This data file contains 32 variables and 8,601 cases. This file contains UPC values on the packages of tobacco products used or in the possession of adult respondents at the time of Wave 1. The UPC values can be used to identify and validate the specific products used by respondents and augment the analyses of the characteristics of tobacco products used

About OPCRD

Optimum Patient Care Research Database (OPCRD) is a real-world, longitudinal, research database that provides anonymised data to support scientific, medical, public health and exploratory research. OPCRD is established, funded and maintained by Optimum Patient Care Limited (OPC) – which is a not-for-profit social enterprise that has been providing quality improvement programmes and research support services to general practices across the UK since 2005.

Key Features of OPCRD

OPCRD has been purposefully designed to facilitate real-world data collection and address the growing demand for observational and pragmatic medical research, both in the UK and internationally. Data held in OPCRD is representative of routine clinical care and thus enables the study of ‘real-world’ effectiveness and health care utilisation patterns for chronic health conditions.

OPCRD unique qualities which set it apart from other research data resources: • De-identified electronic medical records of more than 24.9 million patients • OPCRD covers all major UK primary care clinical systems • OPCRD covers approximately 35% of the UK population • One of the biggest primary care research networks in the world, with over 1,175 practices • Linked patient reported outcomes for over 68,000 patients including Covid-19 patient reported data • Linkage to secondary care data sources including Hospital Episode Statistics (HES)

Data Available in OPCRD

OPCRD has received data contributions from over 1,175 practices and currently holds de-identified research ready data for over 24.9 million patients or data subjects. This includes longitudinal primary care patient data and any data relevant to the management of patients in primary care, and thus covers all conditions. The data is derived from both electronic health records (EHR) data and patient reported data from patient questionnaires delivered as part of quality improvement. OPCRD currently holds over 68,000 patient reported questionnaire data on Covid-19, asthma, COPD and rare diseases.

Approvals and Governance

OPCRD has NHS research ethics committee (REC) approval to provide anonymised data for scientific and medical research since 2010, with its most recent approval in 2020 (NHS HRA REC ref: 20/EM/0148). OPCRD is governed by the Anonymised Data Ethics and Protocols Transparency committee (ADEPT). All research conducted using anonymised data from OPCRD must gain prior approval from ADEPT. Proceeds from OPCRD data access fees and detailed feasibility assessments are re-invested into OPC services for the continued free provision of patient quality improvement programmes for contributing practices and patients.

For more information on OPCRD please visit: https://opcrd.co.uk/

Step-by-step instructions for CoLab members on navigating the Sepsis CoLab's Dataverse, downloading existing assets, requesting a new Dataverse for your project, uploading or modifying files, and submitting project proposals to access or contribute de-identified clinical datasets. NOTE for restricted files: If you are not yet a CoLab member, please complete our membership application survey to gain access to restricted files within 2 business days. Some files may remain restricted to CoLab members. These files are deemed more sensitive by the file owner and are meant to be shared on a case-by-case basis. Please contact the CoLab coordinator on this page under "collaborate with the pediatric sepsis colab."

Coups d'Ètat are important events in the life of a country. They constitute an important subset of irregular transfers of political power that can have significant and enduring consequences for national well-being. There are only a limited number of datasets available to study these events (Powell and Thyne 2011, Marshall and Marshall 2019). Seeking to facilitate research on post-WWII coups by compiling a more comprehensive list and categorization of these events, the Cline Center for Advanced Social Research (previously the Cline Center for Democracy) initiated the Coup d’État Project as part of its Societal Infrastructures and Development (SID) project. More specifically, this dataset identifies the outcomes of coup events (i.e., realized, unrealized, or conspiracy) the type of actor(s) who initiated the coup (i.e., military, rebels, etc.), as well as the fate of the deposed leader. Version 2.1.3 adds 19 additional coup events to the data set, corrects the date of a coup in Tunisia, and reclassifies an attempted coup in Brazil in December 2022 to a conspiracy. Version 2.1.2 added 6 additional coup events that occurred in 2022 and updated the coding of an attempted coup event in Kazakhstan in January 2022. Version 2.1.1 corrected a mistake in version 2.1.0, where the designation of “dissident coup” had been dropped in error for coup_id: 00201062021. Version 2.1.1 fixed this omission by marking the case as both a dissident coup and an auto-coup. Version 2.1.0 added 36 cases to the data set and removed two cases from the v2.0.0 data. This update also added actor coding for 46 coup events and added executive outcomes to 18 events from version 2.0.0. A few other changes were made to correct inconsistencies in the coup ID variable and the date of the event. Version 2.0.0 improved several aspects of the previous version (v1.0.0) and incorporated additional source material to include: • Reconciling missing event data • Removing events with irreconcilable event dates • Removing events with insufficient sourcing (each event needs at least two sources) • Removing events that were inaccurately coded as coup events • Removing variables that fell below the threshold of inter-coder reliability required by the project • Removing the spreadsheet ‘CoupInventory.xls’ because of inadequate attribution and citations in the event summaries • Extending the period covered from 1945-2005 to 1945-2019 • Adding events from Powell and Thyne’s Coup Data (Powell and Thyne, 2011)
Items in this Dataset 1. Cline Center Coup d'État Codebook v.2.1.3 Codebook.pdf - This 15-page document describes the Cline Center Coup d’État Project dataset. The first section of this codebook provides a summary of the different versions of the data. The second section provides a succinct definition of a coup d’état used by the Coup d'État Project and an overview of the categories used to differentiate the wide array of events that meet the project's definition. It also defines coup outcomes. The third section describes the methodology used to produce the data. Revised February 2024 2. Coup Data v2.1.3.csv - This CSV (Comma Separated Values) file contains all of the coup event data from the Cline Center Coup d’État Project. It contains 29 variables and 1000 observations. Revised February 2024 3. Source Document v2.1.3.pdf - This 325-page document provides the sources used for each of the coup events identified in this dataset. Please use the value in the coup_id variable to identify the sources used to identify that particular event. Revised February 2024 4. README.md - This file contains useful information for the user about the dataset. It is a text file written in markdown language. Revised February 2024
Citation Guidelines 1. To cite the codebook (or any other documentation associated with the Cline Center Coup d’État Project Dataset) please use the following citation: Peyton, Buddy, Joseph Bajjalieh, Dan Shalmon, Michael Martin, Jonathan Bonaguro, and Scott Althaus. 2024. “Cline Center Coup d’État Project Dataset Codebook”. Cline Center Coup d’État Project Dataset. Cline Center for Advanced Social Research. V.2.1.3. February 27. University of Illinois Urbana-Champaign. doi: 10.13012/B2IDB-9651987_V7 2. To cite data from the Cline Center Coup d’État Project Dataset please use the following citation (filling in the correct date of access): Peyton, Buddy, Joseph Bajjalieh, Dan Shalmon, Michael Martin, Jonathan Bonaguro, and Emilio Soto. 2024. Cline Center Coup d’État Project Dataset. Cline Center for Advanced Social Research. V.2.1.3. February 27. University of Illinois Urbana-Champaign. doi: 10.13012/B2IDB-9651987_V7

About this dataset

Context

The dataset tabulates the Little Valley population over the last 20 plus years. It lists the population for each year, along with the year on year change in population, as well as the change in percentage terms for each year. The dataset can be utilized to understand the population change of Little Valley across the last two decades. For example, using this dataset, we can identify if the population is declining or increasing. If there is a change, when the population peaked, or if it is still growing and has not reached its peak. We can also compare the trend with the overall trend of United States population over the same period of time.

Key observations

In 2022, the population of Little Valley was 1,090, a 0.28% increase year-by-year from 2021. Previously, in 2021, Little Valley population was 1,087, a decline of 0.46% compared to a population of 1,092 in 2020. Over the last 20 plus years, between 2000 and 2022, population of Little Valley decreased by 31. In this period, the peak population was 1,140 in the year 2010. The numbers suggest that the population has already reached its peak and is showing a trend of decline. Source: U.S. Census Bureau Population Estimates Program (PEP).

Content

When available, the data consists of estimates from the U.S. Census Bureau Population Estimates Program (PEP).

Data Coverage:

• From 2000 to 2022

Variables / Data Columns

• Year: This column displays the data year (Measured annually and for years 2000 to 2022)
• Population: The population for the specific year for the Little Valley is shown in this column.
• Year on Year Change: This column displays the change in Little Valley population for each year compared to the previous year.
• Change in Percent: This column displays the year on year change as a percentage. Please note that the sum of all percentages may not equal one due to rounding of values.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Little Valley Population by Year. You can refer the same here

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance publicly available dataset has 33 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors. This dataset requires a registration process and a data use agreement.

CDC has three COVID-19 case surveillance datasets:

• COVID-19 Case Surveillance Public Use Data with Geography: Public use, patient-level dataset with clinical data (including symptoms), demographics, and county and state of residence. (19 data elements)
• COVID-19 Case Surveillance Public Use Data: Public use, patient-level dataset with clinical and symptom data and demographics, with no geographic data. (12 data elements)
• COVID-19 Case Surveillance Restricted Access Detailed Data: Restricted access, patient-level dataset with clinical and symptom data, demographics, and state and county of residence. Access requires a registration process and a data use agreement. (33 data elements)

Requesting Access to the COVID-19 Case Surveillance Restricted Access Detailed Data Please review the following documents to determine your interest in accessing the COVID-19 Case Surveillance Restricted Access Detailed Data file: 1) CDC COVID-19 Case Surveillance Restricted Access Detailed Data: Summary, Guidance, Limitations Information, and Restricted Access Data Use Agreement Information 2) Data Dictionary for the COVID-19 Case Surveillance Restricted Access Detailed Data The next step is to complete the Registration Information and Data Use Restrictions Agreement (RIDURA). Once complete, CDC will review your agreement. After access is granted, Ask SRRG (eocevent394@cdc.gov) will email you information about how to access the data through GitHub. If you have questions about obtaining access, email eocevent394@cdc.gov.

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

COVID-19 case surveillance data are collected by jurisdictions and are shared voluntarily with CDC. For more information, visit: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.

The deidentified data in the restricted access dataset include demographic characteristics, state and county of residence, any exposure history, disease severity indicators and outcomes, clinical data, laboratory diagnostic test results, and comorbidities.

All data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.

COVID-19 case reports have been routinely submitted using standardized case reporting forms.

On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19 included. Current versions of these case definitions are available here: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/.

CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification. All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for lab-confirmed or probable cases.

On May 5, 2020, the standardized case reporting form was revised. Case reporting using this new form is ongoing among U.S. states and territories.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.

Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question "Was the individual hospitalized?" where the possible answer choices include "Yes," "No," or "Unknown," the blank value is recoded to "Missing" because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race, ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<11 COVID-19 case records with a given values). Suppression includes low frequency combinations of case month, geographic characteristics (county and state of residence), and demographic characteristics (sex, age group, race, and ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These and other COVID-19 data are available from multiple public locations:

This project includes three datasets: the first dataset compiles dataset metadata commonalities that were identified from 48 Canadian restricted health data sources. The second dataset compiles access process metadata commonalities extracted from the same 48 data sources. The third dataset maps metadata commonalities of the first dataset to existing metadata standards including DataCite, DDI, DCAT, and DATS. This mapping exercise was completed to determine whether metadata used by restricted data sources aligned with existing standards for research data.

The Medicare Current Beneficiary Survey (MCBS) - Survey File Microdata Public Use File (PUF) dataset provides information on topics such as Medicare beneficiaries' access to care, health status, other information regarding beneficiaries’ knowledge of, attitudes toward, and satisfaction with their health care, as well as demographic data and information on all types of health insurance coverage.Resources for Using and Understanding the DataThis dataset is based on information from the MCBS and administrative data. The MCBS is a continuous, multi-purpose longitudinal survey covering a representative national sample of the Medicare population, including the population of beneficiaries aged 65 and over and beneficiaries aged 64 and below with certain disabling conditions. The MCBS collects this information in three data collection periods, or rounds, per year. Disclosure protections have been applied to the file, including de-identification and other methods. As a result, the MCBS Survey File Microdata file does not require a Data Use Agreement (DUA). In contrast, the MCBS Limited Data Set (LDS) releases contain beneficiary-level protected health information (PHI) and therefore require a DUA. The MCBS - Survey File Microdata file is not intended to replace the more detailed LDS files but, rather, it makes available a general-use publicly-available alternative that provides the highest degree of protection to the Medicare beneficiaries’ PHI. The main benefits of using the MCBS - Survey File Microdata file are:Increased data access for researchers of the MCBS through a free file download that is consistent with other U.S. Department of Health and Human Services (HHS) public-use survey files.Enhanced potential for policy-relevant analyses, by attracting new researchers and policymakers. Accessing the MCBS LDS can be a significant deterrent due to the associated costs and time but the MCBS - Survey File Microdata file mitigates these barriers to encourage broader utilization. A link to the more detailed MCBS LDS files is provided in the Resources section on this page. MCBS LDS data are also presented in the MCBS Chartbook linked in the Visualization section on this page.

This dataset consists of single source and mixture samples which were genotyped/sequenced with kits targeting Forensic DNA markers. More information specific to the kit and or method used can be found in the README text files included in each zipped file. The CE-STR kits reported for the single source samples include: Applied Biosystems GlobalFiler, Applied Biosystems Y-Filer Plus, Promega PowerPlex Fusion 6C, Promega PowerPlex Y23 The CE profiles for single source samples are also included in a spreadsheet. The following CE-STR kit is reported for the mixture samples: Promega PowerPlex Fusion 6C The sequencing kits reported for the mixture and single source samples include: Verogen ForenSeq DNA Signature Prep Kit, Promega PowerSeq 46GY, Thermo Fisher Applied Biosystems Precision ID GlobalFiler NGS STR Panel v2 The single source samples only are reported for: Promega PowerSeq CRM Nested System This data was produced with approval from the NIST Research Protections Office. It is intended for research, training, and educational purposes only and could potentially contain errors due to limited review prior to uploading. This data should not be used to identify the donor of the profile or uploaded/searched versus public or law enforcement DNA databases. Certain commercial equipment, instruments, or materials are identified in this dataset in order to specify the experimental procedure adequately. Such identification is not intended to imply recommendation or endorsement by NIST, nor is it intended to imply that the materials or equipment identified are necessarily the best available for the purpose.

About this dataset

Context

The dataset tabulates the population of Little Falls by race. It includes the population of Little Falls across racial categories (excluding ethnicity) as identified by the Census Bureau. The dataset can be utilized to understand the population distribution of Little Falls across relevant racial categories.

Key observations

The percent distribution of Little Falls population by race (across all racial categories recognized by the U.S. Census Bureau): 88.53% are white, 1.69% are Black or African American, 0.07% are Asian, 0.55% are Native Hawaiian and other Pacific Islander, 2.63% are some other race and 6.55% are multiracial.

Content

When available, the data consists of estimates from the U.S. Census Bureau American Community Survey (ACS) 2019-2023 5-Year Estimates.

Racial categories include:

• White
• Black or African American
• American Indian and Alaska Native
• Asian
• Native Hawaiian and Other Pacific Islander
• Some other race
• Two or more races (multiracial)

Variables / Data Columns

• Race: This column displays the racial categories (excluding ethnicity) for the Little Falls
• Population: The population of the racial category (excluding ethnicity) in the Little Falls is shown in this column.
• % of Total Population: This column displays the percentage distribution of each race as a proportion of Little Falls total population. Please note that the sum of all percentages may not equal one due to rounding of values.

Good to know

Margin of Error

Data in the dataset are based on the estimates and are subject to sampling variability and thus a margin of error. Neilsberg Research recommends using caution when presening these estimates in your research.

Custom data

If you do need custom data for any of your research project, report or presentation, you can contact our research staff at research@neilsberg.com for a feasibility of a custom tabulation on a fee-for-service basis.

Inspiration

Neilsberg Research Team curates, analyze and publishes demographics and economic data from a variety of public and proprietary sources, each of which often includes multiple surveys and programs. The large majority of Neilsberg Research aggregated datasets and insights is made available for free download at https://www.neilsberg.com/research/.

Recommended for further research

This dataset is a part of the main dataset for Little Falls Population by Race & Ethnicity. You can refer the same here

Data set for "Journal editors: How do their editing incomes compare?". Data provided is a limited de-identified dataset.

Note: Reporting of new COVID-19 Case Surveillance data will be discontinued July 1, 2024, to align with the process of removing SARS-CoV-2 infections (COVID-19 cases) from the list of nationally notifiable diseases. Although these data will continue to be publicly available, the dataset will no longer be updated.

Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Kentucky (1/1/24), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This case surveillance public use dataset has 19 elements for all COVID-19 cases shared with CDC and includes demographics, geography (county and state of residence), any exposure history, disease severity indicators and outcomes, and presence of any underlying medical conditions and risk behaviors.

Currently, CDC provides the public with three versions of COVID-19 case surveillance line-listed data: this 19 data element dataset with geography, a 12 data element public use dataset, and a 33 data element restricted access dataset.

The following apply to the public use datasets and the restricted access dataset:

• Data elements can be found on the COVID-19 case report form located at www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf.
• Data are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers.
• Some data are suppressed to protect individual privacy.
• Datasets will include all cases with the earliest date available in each record (date received by CDC or date related to illness/specimen collection) at least 14 days prior to the creation of the current datasets. This 14-day lag allows case reporting to be stabilized and ensure that time-dependent outcome data are accurately captured.
• Datasets are updated monthly.
• Datasets are created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access and include protections designed to protect individual privacy.
• For more information about data collection and reporting, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/about-us-cases-deaths.html.
• For more information about the COVID-19 case surveillance data, please see https://www.cdc.gov/coronavirus/2019-ncov/covid-data/faq-surveillance.html
  

Overview

The COVID-19 case surveillance database includes individual-level data reported to U.S. states and autonomous reporting entities, including New York City and the District of Columbia (D.C.), as well as U.S. territories and affiliates. On April 5, 2020, COVID-19 was added to the Nationally Notifiable Condition List and classified as “immediately notifiable, urgent (within 24 hours)” by a Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement (Interim-20-ID-01). CSTE updated the position statement on August 5, 2020, to clarify the interpretation of antigen detection tests and serologic test results within the case classification (Interim-20-ID-02). The statement also recommended that all states and territories enact laws to make COVID-19 reportable in their jurisdiction, and that jurisdictions conducting surveillance should submit case notifications to CDC. COVID-19 case surveillance data are collected by jurisdictions and reported voluntarily to CDC.

For more information: NNDSS Supports the COVID-19 Response | CDC.

COVID-19 Case Reports COVID-19 case reports are routinely submitted to CDC by public health jurisdictions using nationally standardized case reporting forms. On April 5, 2020, CSTE released an Interim Position Statement with national surveillance case definitions for COVID-19. Current versions of these case definitions are available at: https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. All cases reported on or after were requested to be shared by public health departments to CDC using the standardized case definitions for lab-confirmed or probable cases. On May 5, 2020, the standardized case reporting form was revised. States and territories continue to use this form.

Data are Considered Provisional

• The COVID-19 case surveillance data are dynamic; case reports can be modified at any time by the jurisdictions sharing COVID-19 data with CDC. CDC may update prior cases shared with CDC based on any updated information from jurisdictions. For instance, as new information is gathered about previously reported cases, health departments provide updated data to CDC. As more information and data become available, analyses might find changes in surveillance data and trends during a previously reported time window. Data may also be shared late with CDC due to the volume of COVID-19 cases.
• Annual finalized data: To create the final NNDSS data used in the annual tables, CDC works carefully with the reporting jurisdictions to reconcile the data received during the year until each state or territorial epidemiologist confirms that the data from their area are correct.

Access Addressing Gaps in Public Health Reporting of Race and Ethnicity for COVID-19, a report from the Council of State and Territorial Epidemiologists, to better understand the challenges in completing race and ethnicity data for COVID-19 and recommendations for improvement.

Data Limitations

To learn more about the limitations in using case surveillance data, visit FAQ: COVID-19 Data and Surveillance.

Data Quality Assurance Procedures

CDC’s Case Surveillance Section routinely performs data quality assurance procedures (i.e., ongoing corrections and logic checks to address data errors). To date, the following data cleaning steps have been implemented:

• Questions that have been left unanswered (blank) on the case report form are reclassified to a Missing value, if applicable to the question. For example, in the question "Was the individual hospitalized?" where the possible answer choices include "Yes," "No," or "Unknown," the blank value is recoded to "Missing" because the case report form did not include a response to the question.
• Logic checks are performed for date data. If an illogical date has been provided, CDC reviews the data with the reporting jurisdiction. For example, if a symptom onset date in the future is reported to CDC, this value is set to null until the reporting jurisdiction updates the date appropriately.
• Additional data quality processing to recode free text data is ongoing. Data on symptoms, race, ethnicity, and healthcare worker status have been prioritized.

Data Suppression

To prevent release of data that could be used to identify people, data cells are suppressed for low frequency (<11 COVID-19 case records with a given values). Suppression includes low frequency combinations of case month, geographic characteristics (county and state of residence), and demographic characteristics (sex, age group, race, and ethnicity). Suppressed values are re-coded to the NA answer option; records with data suppression are never removed.

Additional COVID-19 Data

COVID-19 data are available to the public as summary or aggregate count files, including total counts of cases and deaths by state and by county. These and other COVID-19 data are available from multiple public locations: COVID Data Tracker; United States COVID-19 Cases and Deaths by State; COVID-19 Vaccination Reporting Data Systems; and COVID-19 Death Data and Resources.

Notes:

March 1, 2022: The "COVID-19 Case Surveillance Public Use Data with Geography" will be updated on a monthly basis.

April 7, 2022: An adjustment was made to CDC’s cleaning algorithm for COVID-19 line level case notification data. An assumption in CDC's algorithm led to misclassifying deaths that were not COVID-19 related. The algorithm has since been revised, and this dataset update reflects corrected individual level information about death status for all cases collected to date.

June 25, 2024: An adjustment

This dataset release is comprised of de-identified data from March 2014 - September 2015 of Canvas Network open courses, along with related documentation. In balancing data utility with thorough de-identification, this dataset favors utility; therefore, access and usage of this dataset is restricted as described in the Canvas Network Data Usage Agreement. These data use a star schema to organize various course, activity, and person records using dimensions and facts. The structure of this dataset is based on the Canvas Data star schema as described in https://portal.inshosteddata.com/docs. The first release of this dataset is the Canvas Network Courses, Activities, and Users (4/2014 - 9/2015) Dataset, version 1.0, created on March 3, 2016. The data set is split into multiple files for convenience: CNCAU_1403-1509_R_v1_03-03-2016.tgz contains the facts and dimensions representing the breadth of the dataset CNCAU_1403-1509_R_v1_03-03-2016_requests-01.gz - ...08.gz contain user page view requests The resulting files are plain text, with tab-separated values.

The California Department of Public Health (CDPH) aggregates confirmed cases of COVID-19 by sewershed restricted locations. Confirmed cases are defined as individuals with a positive molecular test, which tests for viral genetic material, such as a polymerase chain reaction test.

Since wastewater data available starts from January 1st, 2021, rather than the beginning of the COVID-19 pandemic in 2020, the cumulative counts of the confirmed cases variable are shown as “NA”.

Please note that values less than 5 for confirmed cases are masked (shown as “Masked”) if the sewershed population size is 50,000 or fewer, in accordance with de-identification guidelines. Values less than 3 for cases are masked (shown as “Masked”) if the sewershed population size is between 50,001 and 250,000. For no confirmed cases reported, values are set as zero.

This is the dataset presented in the following manuscript: The Surface Water Chemistry (SWatCh) database: A standardized global database of water chemistry to facilitate large-sample hydrological research, which is currently under review at Earth System Science Data.

Openly accessible global scale surface water chemistry datasets are urgently needed to detect widespread trends and problems, to help identify their possible solutions, and determine critical spatial data gaps where more monitoring is required. Existing datasets are limited in availability, sample size/sampling frequency, and geographic scope. These limitations inhibit the answering of emerging transboundary water chemistry questions, for example, the detection and understanding of delayed recovery from freshwater acidification. Here, we begin to address these limitations by compiling the global surface water chemistry (SWatCh) database. We collect, clean, standardize, and aggregate open access data provided by six national and international agencies to compile a database containing information on sites, methods, and samples, and a GIS shapefile of site locations. We remove poor quality data (for example, values flagged as “suspect” or “rejected”), standardize variable naming conventions and units, and perform other data cleaning steps required for statistical analysis. The database contains water chemistry data for streams, rivers, canals, ponds, lakes, and reservoirs across seven continents, 24 variables, 33,722 sites, and over 5 million samples collected between 1960 and 2022. Similar to prior research, we identify critical spatial data gaps on the African and Asian continents, highlighting the need for more data collection and sharing initiatives in these areas, especially considering freshwater ecosystems in these environs are predicted to be among the most heavily impacted by climate change. We identify the main challenges associated with compiling global databases – limited data availability, dissimilar sample collection and analysis methodology, and reporting ambiguity – and provide recommended solutions. By addressing these challenges and consolidating data from various sources into one standardized, openly available, high quality, and trans-boundary database, SWatCh allows users to conduct powerful and robust statistical analyses of global surface water chemistry.

BackgroundPlague is a zoonotic disease that, despite affecting humans for more than 5000 years, has historically been the subject of limited drug development activity. Drugs that are currently recommended in treatment guidelines have been approved based on animal studies alone–no pivotal clinical trials in humans have yet been completed. As a result of the sparse clinical research attention received, there are a number of methodological challenges that need to be addressed in order to facilitate the collection of clinical trial data that can meaningfully inform clinicians and policy-makers. One such challenge is the identification of clinically-relevant endpoints, which are informed by understanding the clinical characterisation of the disease–how it presents and evolves over time, and important patient outcomes, and how these can be modified by treatment.Methodology/Principal findingsThis systematic review aims to summarise the clinical profile of 1343 patients with bubonic plague described in 87 publications, identified by searching bibliographic databases for studies that meet pre-defined eligibility criteria. The majority of studies were individual case reports. A diverse group of signs and symptoms were reported at baseline and post-baseline timepoints–the most common of which was presence of a bubo, for which limited descriptive and longitudinal information was available. Death occurred in 15% of patients; although this varied from an average 10% in high-income countries to an average 17% in low- and middle-income countries. The median time to death was 1 day, ranging from 0 to 16 days.Conclusions/SignificanceThis systematic review elucidates the restrictions that limited disease characterisation places on clinical trials for infectious diseases such as plague, which not only impacts the definition of trial endpoints but has the knock-on effect of challenging the interpretation of a trial’s results. For this reason and despite interventional trials for plague having taken place, questions around optimal treatment for plague persist.